CTEC Global X CleanTech ETF

HAYWARD, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC) today announced that it will release its fiscal 2007 third quarter financial results prior to the market's opening on Wednesday, January 31, 2007. The Company will also host a conference call and webcast available to all interested parties at 7:00 a.m. PT. The dial-in number to access the call is (800) 896-8445 or, from international locations, +1-785-830-1916. Alternatively, you may go to the Cholestech website, http://www.cholestech.com/ for the link to the webcast. Cholestech's fiscal 2007 third quarter financial results may be accessed by: News Release: Visit the Cholestech website or call Financial Dynamics at (415) 439-4500 to have a copy of the news release faxed or emailed. Conference Call: Dial (800) 896-8445 or, from international locations, +1-785-830-1916 prior to the start of the call at 7:00 a.m. PT. The call will also be webcast live at http://www.cholestech.com/. Please visit the site prior to the broadcast to ensure your connection. Replay: The conference call replay will be available by telephone through Wednesday, February 14th until 9:00 p.m. PT. To access the conference call replay, dial (800) 839-2457 or from international locations, +1-402-220-7217. There is no pass code required. A web archive of the call will also be made available at Cholestech's website. For additional information on Cholestech, visit the Company's website http://www.cholestech.com/. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) System and the GDX(TM) System(1), which is approved for prescription home use and for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. (1) GDX is 510(k) cleared for prescription home use and, accordingly, is CLIA waived Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at http://www.cholestech.com/. DATASOURCE: Cholestech Corporation CONTACT: Jack Glenn, Chief Financial Officer of Cholestech Corporation, +1-510-781-5065, or ; or Investors, Brendan Lahiff of Financial Dynamics, +1-415-439-4504, or , for Cholestech Corporation Web site: http://www.cholestech.com/

Copyright